Wayne Kuznar | Authors


Unique Immunotherapy Combos Evaluated in Advanced Melanoma

July 20, 2021

Immune-checkpoint inhibitor therapy, involving anti–CTLA-4 and anti–PD-1/ PD-L1 agents, has transformed the treatment of melanoma. Nonetheless, even with combination anti–PD-1 and anti–CTLA-4 therapy, nearly 50% of patients die of their disease at 5 years.

Axi-Cel Treatment Outcomes Correlate With Response to Prior Therapy in Refractory Large B-Cell Lymphoma

February 09, 2021

Treatment with axicabtagene ciloleucel is less likely to induce responses in patients with refractory large B-cell lymphoma who have never achieved a complete response to any line of prior therapy, according to findings from a single-center retrospective analysis.

Patients With Metastatic RCC Receive TKIs or mTOR Inhibitors After Immunotherapy

February 18, 2020

Most patients with metastatic renal cell carcinoma whose disease progresses after immunotherapy given either alone or in combination with other agents receive subsequent treatment with VEGF tyrosine kinase inhibitors or mTOR inhibitors. When administered post-immunotherapy, cabozantinib is associated with superior median progression free survival, according to retrospective data from a real-world study of patients treated at 16 Italian referral centers.